WALTHAM, Mass., March 10, 2020 – Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that David H. Donabedian, Ph.D., Co-founder and Chief Executive Officer of Axial Biotherapeutics will present a virtual company overview and participate in a virtual panel on “Modulating the Microbiome” at the Chardan 2nd Annual Microbiome Medicines Summit on Monday, March 16, 2020 at 8:45 AM ET and 12:40 PM ET, respectively.

A recording of the presentation and panel can be accessed at http://bit.ly/2v8qwB1.

About Axial Biotherapeutics
Axial Biotherapeutics is a clinical stage biopharmaceutical company pioneering novel science focused on the interaction between the brain and the gut to mitigate the causes and symptoms of the central nervous system (CNS) and other gut-derived diseases. The Company has built a pipeline of novel smallmolecules and live biotherapeutics with lead programs to address the significant unmet patient needs associated with Parkinson’s Disease (PD) and Autism Spectrum Disorder (ASD).

Investor Contact:
Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
julie.seidel@sternir.com